ADBIC
GSK icon

A.D. Beadell Investment Counsel’s GSK GSK Stock Holding History

A.D. Beadell Investment Counsel’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-12,496
Closed -$610K – 89
2018
Q1 		$610K Sell
12,496
-5,200
-29% -$242K 0.53% 65
2017
Q4 		$784K Sell
17,696
-1,476
-8% -$68.2K 0.64% 51
2017
Q3 		$972K Sell
19,172
-5,000
-21% -$254K 0.83% 43
2017
Q2 		$1.3M Sell
24,172
-400
-2% -$21.3K 1.05% 36
2017
Q1 		$1.29M Sell
24,572
-480
-2% -$24.4K 1.07% 37
2016
Q4 		$1.21M Sell
25,052
-800
-3% -$39.5K 1.03% 36
2016
Q3 		$1.39M Hold
25,852
– – 1.16% 33
2016
Q2 		$1.4M Sell
25,852
-400
-2% -$21.1K 1.14% 33
2016
Q1 		$1.33M Hold
26,252
– – 1.22% 33
2015
Q4 		$1.32M Sell
26,252
-1,560
-6% -$79.5K 1.16% 34
2015
Q3 		$1.34M Sell
27,812
-1,920
-6% -$99.9K 1.21% 31
2015
Q2 		$1.55M Hold
29,732
– – 1.24% 28
2015
Q1 		$1.72M Sell
29,732
-856
-3% -$49.1K 1.33% 25
2014
Q4 		$1.63M Sell
30,588
-7,000
-19% -$392K 1.24% 26
2014
Q3 		$2.16M Buy
37,588
+28,696
+323% +$1.76M 1.64% 14
2014
Q2 		$594K Buy
+8,892
New +$602K 0.44% 70

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

A.D. Beadell Investment Counsel's GSK Position: Q2 2018 in Review

A.D. Beadell Investment Counsel sold out of GSK (GSK) in Q2 2018, closing a stake of 12,496 shares — an estimated $610K sold.

A.D. Beadell Investment Counsel first reported a position in GSK in Q2 2014 and held it in 16 quarters. The position peaked at $2.16M in Q3 2014. 787 funds tracked by Wall St. Rank hold GSK as of Q2 2018.

  • A.D. Beadell Investment Counsel reported no remaining GSK position as of Q2 2018 after selling out during the quarter.
  • A.D. Beadell Investment Counsel sold 12,496 GSK shares in Q2 2018, an estimated $610K.
  • A.D. Beadell Investment Counsel first reported a position in GSK in Q2 2014 and held it in 16 quarters.
  • A.D. Beadell Investment Counsel's GSK position peaked at $2.16M in Q3 2014.
  • 787 funds tracked by Wall St. Rank held GSK as of Q2 2018.

Based on A.D. Beadell Investment Counsel's 13F filing for Q2 2018, filed 19 Jul 2018.